Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

890810C

Avanti

18:0 DDAB

Avanti Research™ - A Croda Brand 890810C

Sinônimo(s):

Dimethyldioctadecylammonium (Bromide Salt)

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C38H80NBr
Número CAS:
3700-67-2
Peso molecular:
630.95
Número MDL:
MFCD00041975
Código UNSPSC:
12352211
NACRES:
NA.25

Formulário

liquid

embalagem

pkg of 1 × 2.5 mL (890810C-25mg)
pkg of 2 × 4 mL (890810C-200mg)

fabricante/nome comercial

Avanti Research™ - A Croda Brand 890810C

concentração

10 mg/mL (890810C-25mg)
25 mg/mL (890810C-200mg)

tipo de lipídio

cationic lipids
transfection

Condições de expedição

dry ice

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]

InChI

1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1

chave InChI

PSLWZOIUBRXAQW-UHFFFAOYSA-M

Descrição geral

18:0 DDAB is a cationic lipid and a quaternary ammonium salt. The hydrocarbon tails are saturated, unlike the ionizable lipids. 18:0 DDAB acts as an active nasal adjuvant.

Aplicação

18:0 DDAB or Dimethyldioctadecylammonium (Bromide Salt) has been used to perform transfection of S2 cells.

Ações bioquímicas/fisiológicas

18:0 DDAB is a surface-active molecule, used as an adjuvant to induce a systemic immune response. It is non-toxic.

Embalagem

5 mL Clear Glass Sealed Ampule (890810C-200mg)
5 mL Clear Glass Sealed Ampule (890810C-25mg)

Outras notas

For R&D use only. Not for drug, household, or other uses.

Informações legais

Avanti Research is a trademark of Avanti Polar Lipids, LLC

geralmente comprado junto com este produto

Nº do produto
Descrição
Preços

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Órgãos-alvo

Central nervous system, Liver,Kidney

Classe de risco de água (WGK)

WGK 3

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Sarah E McNeil et al.
Journal of pharmaceutical sciences, 100(5), 1856-1865 (2011-03-05)
The adjuvanticity of liposomes can be directed through formulation to develop a safe yet potent vaccine candidate. With the addition of the cationic lipid dimethyldioctadecylammonium bromide (DDA) to stable neutral distearoylphosphatidylcholine (DSPC):cholesterol (Chol) liposomes, vesicle size reduces while protein entrapment
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Anne Gallez et al.
International journal of pharmaceutics, 573, 118861-118861 (2019-11-26)
The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica